Skip to content

Effectiveness and Safety of CT-guided Needle Placement in the Liver With the Aid of the ActiSight Needle Guidance System

Confirmation of Clinical Effectiveness and Safety of CT-guided Needle Placement in the Liver With the Aid of the ActiSight Needle Guidance System

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01367392
Enrollment
20
Registered
2011-06-07
Start date
2011-06-30
Completion date
2012-01-31
Last updated
2012-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Accurate Navigation to the Lesion

Brief summary

The purpose of this study is to confirm the safety and effectiveness of the ActiSight™ Needle Guidance System with CT-guided percutaneous (through the skin) liver biopsies and ablations . The device used in this study is designed to assist the physician in guiding the needle towards the suspected area. This device does not change the procedure of liver biopsy or ablation. The only difference is that a small adhesive pad is placed on the skin and a miniature video camera is attached to the end of the needle. This camera does not enter the body.

Interventions

DEVICEbiopsy or ablation

biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system

Sponsors

ActiViews Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male or non-pregnant female subjects, between the ages of 18 and 80 at the time of enrollment. * Subjects scheduled for clinically indicated CT guided percutaneous needle placements in the liver who meet the desired target population described above. * Written informed consent to participate in the study. * Ability to comply with the requirements of the study procedures. * Verified home address and phone number to facilitate study follow-up.

Exclusion criteria

* Significant coagulopathy that cannot be adequately corrected. * Subjects who participated in an active stage of any drug, intervention or treatment trial within 30 days of enrollment. * Subjects with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study. * Subjects who are uncooperative or cannot follow instructions. * Mental state that may preclude completion of the study procedure. * Pregnant or nursing female subjects.

Design outcomes

Primary

MeasureTime frameDescription
accuracyduring the procedureFrequency of placing the needle at a location suitable for the planned intervention, as determined by the investigator reviewing the CT images.

Secondary

MeasureTime frameDescription
timeduring the procedureTotal CT-Guided procedure time, starting with scan for entry point planning;
radiationduring the procedureSubject radiation exposure during the procedure
total number of scansduring the procedureNumber of CT scans during the procedure

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026